Status: Recruiting
Safety, Efficacy, & Use of ViviGen Cellular Bone Matrix Allograft in Orthopaedic Fracture Care
Prospective registry and retrospective data collection study to assess the efficacy and safety of Vivigen Cellular Bone Matrix (Vivigen) in orthopaedic trauma patients who require bone grafting in the acute, delayed, non-union fracture as well as use in fusion procedure settings.
Participants needed: 250
Trial details
Biological sex: AllType: ObservationalSponsor: LifeNet HealthUpdated: Apr 2, 2025Locations: 4Duration: 24 Months
Eligibility criteria
Any skeletally mature patient treated with Vivigen bone graft in the setting of...
Patients unable to understand either an English or Spanish consent will be exclu... [+1]